Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Alexander Vugler; James O'connell; Mai Anh Nguyen; Dietmar Weitz; Thomas Leeuw; Elizabeth Hickford; Alexander Verbitsky; Xiaoyou Ying; Markus Rehberg; Bruce Carrington; Mark Merriman; Andrew Moss; Jean-Marie Nicolas; Phil Stanley; Sara Wright; Tim Bourne; Yann Foricher; Zhaoning Zhu; Daniel Brookings; Helen Horsley; Jag Heer; Laurent Schio; Matthias Herrmann; Srinivas Rao; Markus Kohlmann; Peter Florian

doi:10.3389/fphar.2024.1479557

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Front Pharmacol. 2024 Oct 16:15:1479557. doi: 10.3389/fphar.2024.1479557. eCollection 2024.

Authors

Alexander Vugler¹, James O'connell², Mai Anh Nguyen³, Dietmar Weitz⁴, Thomas Leeuw⁵, Elizabeth Hickford⁶, Alexander Verbitsky⁷, Xiaoyou Ying⁷, Markus Rehberg⁸, Bruce Carrington², Mark Merriman¹, Andrew Moss⁹, Jean-Marie Nicolas¹⁰, Phil Stanley¹, Sara Wright¹¹, Tim Bourne¹², Yann Foricher¹³, Zhaoning Zhu¹⁴, Daniel Brookings¹⁴, Helen Horsley¹⁴, Jag Heer¹⁴, Laurent Schio¹³, Matthias Herrmann⁵, Srinivas Rao⁷, Markus Kohlmann¹⁵, Peter Florian⁵

Affiliations

¹ Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
² Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
³ Sanofi R&D, TMED Pharmacokinetics Dynamics and Metabolism, Frankfurt am Main, Germany.
⁴ Sanofi R&D, Drug Metabolism and Pharmacokinetics, Frankfurt am Main, Germany.
⁵ Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany.
⁶ Development Science, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
⁷ Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States.
⁸ Sanofi R&D, Translational Disease Modelling, Frankfurt am Main, Germany.
⁹ Translational Medicine Immunology, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹⁰ Development Science, Drug Metabolism and Pharmacokinetics, UCB Pharma, Braine-I'Alleud, Belgium.
¹¹ Early PV Missions, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹² Milvuswood Consultancy, Penn, United Kingdom.
¹³ Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France.
¹⁴ Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹⁵ Sanofi R&D, Early Clinical Development, Therapeutic Area Immunology and Inflammation, Frankfurt am Main, Germany.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.1037983.].

Keywords: TNF; TNF trimer; immunogenicity; rheumatoid arthritis; small molecule.

Copyright © 2024 Vugler, O’connell, Nguyen, Weitz, Leeuw, Hickford, Verbitsky, Ying, Rehberg, Carrington, Merriman, Moss, Nicolas, Stanley, Wright, Bourne, Foricher, Zhu, Brookings, Horsley, Heer, Schio, Herrmann, Rao, Kohlmann and Florian.

Publication types

Published Erratum